Cristin-prosjekt-ID: 544446
Registrert av: REK Sist endret: 7. oktober 2020 20:57 Sist endret av: REK

Cristin-prosjekt-ID: 544446
Registrert av: REK Sist endret: 7. oktober 2020 20:57 Sist endret av: REK
Prosjekt

Malariaførebyggjing etter behandling av alvorleg anemi (PDM)

prosjektleder

Bjarne Robberstad
ved Universitetet i Bergen

prosjekteier / koordinerende forskningsansvarlig enhet

  • Universitetet i Bergen

forskningsansvarlige enheter

  • Liverpool School of Tropical Medicine

Godkjenninger

  • Regionale komitéer for medisinsk og helsefaglig forskningsetikk (REK) - 2014/1911

Kategorier

Prosjektkategori

  • Bidragsprosjekt

Helseprosjekttype

Legemiddelstudium - Utprøvingsfase 4

Tidsramme

Aktivt
Start: 1. april 2015 Slutt: 31. desember 2021

Beskrivelse Beskrivelse

Tittel

Malariaførebyggjing etter behandling av alvorleg anemi (PDM)

Populærvitenskapelig sammendrag

Children hospitalised with severe anaemia in Africa are at high risk of readmission or death within 6 months after discharge. No strategy specifically addresses this post-discharge period. We will conduct a trial to determine if 3 months of malaria chemoprevention with monthly 3-day treatment courses of the antimalarial dihydroartemisinin-piperaquine (DP) (PMC-DP) in the post-discharge management of children < 5 years of age admitted with severe anaemia is superior to the standard single 3-day treatment course with artemether-lumefantrine (AL) provided as part of standard in-hospital care around the time of discharge, giving 3 weeks prophylaxis. Design: Multi-centre, 2-arm, placebo-controlled, randomized trial in areas with moderate to intense malaria transmission Uganda and Kenya. Sample size: 2212. Primary endpoint: composite of all-cause readmissions and deaths by 6 months. Cost-effectiveness will be assessed. Results will be important to inform new WHO and national guidelines.

Tittel

Malariaførebyggjing etter behandling av alvorleg anemi (PDM)

Populærvitenskapelig sammendrag

Children hospitalised with severe anaemia in Africa are at high risk of readmission or death within 6 months after discharge. No strategy specifically addresses this post-discharge period. We will conduct a trial to determine if 3 months of malaria chemoprevention with monthly 3-day treatment courses of the antimalarial dihydroartemisinin-piperaquine (DP) (PMC-DP) in the post-discharge management of children < 5 years of age admitted with severe anaemia is superior to the standard single 3-day treatment course with artemether-lumefantrine (AL) provided as part of standard in-hospital care around the time of discharge, giving 3 weeks prophylaxis. Design: Multi-centre, 2-arm, placebo-controlled, randomized trial in areas with moderate to intense malaria transmission Uganda and Kenya. Sample size: 2212. Primary endpoint: composite of all-cause readmissions and deaths by 6 months. Cost-effectiveness will be assessed. Results will be important to inform new WHO and national guidelines.

prosjektdeltakere

prosjektleder

Bjarne Robberstad

  • Tilknyttet:
    Prosjektleder
    ved Universitetet i Bergen
1 - 1 av 1